RT Journal Article
T1 [Oseltamivir for the treatment of influenza in children and adolescents].
T2 Oseltamivir para el tratamiento de la gripe en niños y adolescentes.
A1 Tagarro, Alfredo
A1 Cruz-Cañete, Marta
A1 Otheo, Enrique
A1 Launes, Cristian
A1 Couceiro, José Antonio
A1 Pérez, Carlos
A1 Alfayate, Santiago
A1 en nombre del Grupo de trabajo de Infecciones Respiratorias de la Sociedad Española de Infectología Pediátrica (SEIP), 
A1 Miembros del Grupo de Trabajo de Infecciones Respiratorias de la SEIP que han participado en la revisión del manuscrito, 
K1 Antivirales
K1 Antivirals
K1 Gripe
K1 Influenza
K1 Oseltamivir
K1 Zanamivir
AB Influenza is a generally a benign disease, but occasionally it can cause serious complications. There is controversy about the benefits of antiviral treatment. To provide some recommendations on the treatment with oseltamivir in paediatric patients with influenza, based on the best data available and valid in our environment. The Respiratory Infections Group of the Spanish Society of Paediatric Infectious Diseases carried out a review of the literature. The findings were analysed using the GRADE methodology, and recommendations were made. The systematic use of diagnostic tests for influenza in the outpatient setting, or in the emergency room, in immunocompetent patients with a compatible clinical picture is not recommended. If the aim is to prevent serious events, the use of antivirals is not recommended for the vast majority of healthy and asthmatic patients with influenza or suspected seasonal flu. The systematic use of oseltamivir in patients admitted to hospital with influenza is not recommended. Oseltamivir treatment is recommended in any patients with influenza and pneumonia or severe illness, and critically ill patients, especially during the first 48hours of illness. The treatment of patients with risk factors is recommended, considering their underlying disease. Influenza vaccination, together with basic isolation measures, continue to be the main tool in the prevention of influenza. In some situations, there are sufficient data to issue clear recommendations. In other situations, the data are incomplete, and only allows weak recommendations.
YR 2019
FD 2019-02-21
LK http://hdl.handle.net/10668/13617
UL http://hdl.handle.net/10668/13617
LA es
DS RISalud
RD Apr 6, 2025